SCHEMBL536350

SCHEMBL536350

O=C(O)CCCc1cc(F)c(F)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 3/20 0.50
HDAC1 Q13547 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
FFAR1 O14842 7/20 0.45
FFAR4 Q5NUL3 6/20 0.45
HDAC3 O15379 1/20 0.44
MAPK1 P28482 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC4 P56524 1/20 0.44
SLC6A3 Q01959 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30427892 1.00 F13A1 (0.50) F13A1HDAC1HDAC8FFAR1FFAR4
SCHEMBL26633682 0.94 F13A1 (0.58) F13A1HDAC1HDAC8FFAR1FFAR4
SCHEMBL28259923 0.92 F13A1 (0.61) F13A1HDAC1HDAC8SLC6A3MEN1
SCHEMBL4716462 0.88 NPSR1 (0.52) HDAC1HDAC8FFAR1FFAR4
SCHEMBL29009763 0.85 NPSR1 (0.47) F13A1HDAC1HDAC8FFAR1FFAR4
SCHEMBL29010120 0.85 F13A1 (0.44) F13A1HDAC1HDAC8FFAR1FFAR4
SCHEMBL27816726 0.85 HDAC1 (0.47) F13A1HDAC1HDAC8FFAR1FFAR4
SCHEMBL28085944 0.84 CA2 (0.40) F13A1HDAC1HDAC8FFAR1FFAR4
SCHEMBL29010123 0.81 F13A1 (0.47) F13A1HDAC1HDAC8FFAR1FFAR4
SCHEMBL6956901 0.81 FFAR1 (0.50) F13A1HDAC1HDAC8FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109824546-A BOC- (R) -3- amino -4- (2,4,5- trifluorophenyl) butyric acid is condensed impurity and preparation method thereof 浙江永太科技股份有限公司 2019-05-31 CN claimed
CN-105254519-B Synthesizing method of sitagliptin key intermediate 常州吉恩药业有限公司 2017-05-17 CN claimed
CN-105254519-A Synthesizing method of sitagliptin key intermediate GENCHEM & GENPHARM CHANGZHOU CO LTD 2016-01-20 CN claimed
CN-104130149-A Recycling method of 3-(S)-aminobutyric acid derivative ZHEJIANG CHANGMING PHARMACEUTICAL CO LTD 2014-11-05 CN claimed
EP-4281439-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES The Scripps Research Institute (US) 2023-11-29 EP disclosed
US-20230348378-A1 SMALL MOLECULE ALBUMIN BINDERS OREGON HEALTH & SCIENCE UNIVERSITY 2023-11-02 US disclosed
WO-2023175492-A1 NOVEL INTERMEDIATES AND ITS USE IN MANUFACTURING OF SITAGLIPTIN HIKAL LIMITED (IN) 2023-09-21 WO disclosed
CN-116209433-A Small molecule albumin binding agents 俄勒冈健康科学大学 2023-06-02 CN disclosed
WO-2023012819-A1 RECOMBINANT TRANSAMINASE POLYPEPTIDES QUANTUMZYME LLP (IN) 2023-02-09 WO disclosed
WO-2022159955-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2022-07-28 WO disclosed
WO-2022040607-A1 SMALL MOLECULE ALBUMIN BINDERS OREGON HEALTH & SCIENCE UNIVERSITY (US) 2022-02-24 WO disclosed
CN-109608348-A A kind of synthetic method of (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl) butyric acid 凯瑞斯德生化(苏州)有限公司 2019-04-12 CN disclosed
CN-104130149-A Recycling method of 3-(S)-aminobutyric acid derivative ZHEJIANG CHANGMING PHARMACEUTICAL CO LTD 2014-11-05 CN disclosed
CN-101781274-B Acylated piperazine dipeptidyl peptidase IV inhibitor KBP BIOSCIENCES CO LTD 2013-01-02 CN disclosed
EP-2415754-A2 IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE Dong-A Pharmaceutical Co., Ltd. (KR) 2012-02-08 EP disclosed
WO-2011049344-A2 METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN HANMI HOLDINGS CO., LTD. (KR) 2011-04-28 WO disclosed
EP-2292232-A1 Beta-amino tetrahydroimidazo(1,2-A)pyrazines and tetrahydrotriazolo(4,3-A)pyrazines for use in the treatment of diabetes type II Merck Sharp & Dohme Corp. (US) 2011-03-09 EP disclosed
WO-2010122578-A2 PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES MSN LABORATORIES LIMITED (IN) 2010-10-28 WO disclosed
US-20100048570-A1 THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF Kainos Medicine, Inc (KR) 2010-02-25 US disclosed
US-20100048570-A1 THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF Kainos Medicine, Inc (KR) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348378-A1 SMALL MOLECULE ALBUMIN BINDERS ALB, FABP1, FABP3 F13A1 755/4885HDAC1 2839/4885HDAC8 3528/4885
US-20100048570-A1 THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF DPP4, DPP3, DPP7 F13A1 4695/4885HDAC1 168/4885HDAC8 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.